TOP NEWS: PureTech Health in merger talks with Nektar Therapeutics

(Alliance News) - Clinical-stage biotherapeutics firm PureTech Health PLC on Friday confirmed it ...

Alliance News 7 October, 2022 | 8:51AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Clinical-stage biotherapeutics firm PureTech Health PLC on Friday confirmed it is in combination talks with San Francisco-based biopharmaceutical company Nektar Therapeutics Inc.

PureTech shares fell 17% to 213.50 pence each in London on Friday morning. This compares to Nektar's closing price on Thursday of USD3.38 per share on the Nasdaq in New York.

Puretech has a market capitalisation of GBP596.8 million, Nektar has market capitalisation of USD633.4 million, which is around GBP560.1 million.

The exchanged proposals may include a takeover offer of PureTech, which develops medicines focused on serious diseases.

Boston, Massachusetts-based PureTech noted that Nektar has until November 3 to announce an intention to make an offer, or to announce that it does not intend to make an offer.

In August, PureTech reported a pretax loss in the first half of 2022 to June 30 of USD56.0 million, narrowed by 41% from USD94.9 million a year before. In comparison, Nektar reported a pretax loss of USD249.2 million for the first half of 2022, widened by 0.5% from USD248.0 million.

PureTech's half-year revenue in the first half of 2022 stood at USD7.0 million, up 21% from USD5.8 million. This compares to Nektar's half-year 2022 revenue of USD46.4 million, down 11% from USD52.0 million.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
PureTech Health PLC 222.50 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures